|
|
Takaaki Senbonmatsu, Sahoko Ichihara, Edward Price, F. Andrew Gaffney, Tadashi Inagami
J Clin Invest. 2000;
106(3):R25
doi:10.1172/JCI10037
Abstract |
Full text
| PDF
T
he pathophysiological roles of the angiotensin II type 2 receptor (AT2) in cardiac hypertrophy remain unclear. By the targeted deletion of mouse AT2 we were able to prevent the left ventricular hypertrophy resulting from pressure overload, while cardiac contractile functions remained normal. This implies that AT2 is a mediator of cardiac hypertrophy in response to increased blood pressure. The effects of AT2 deletion were independent of activation of embryonic genes for cardiac hypertrophy. However, p70S6k, one of the key factors in cardiac hypertrophy, was markedly and specifically reduced in the ventricles of Agtr2–/Y mice. We propose that p70S6k plays a major role in AT2-mediated ventricular hypertrophy.This article may have been published online in advance of the print edition. The date of publication is available from the JCI website, http://www.jci.org. J. Clin. Invest. 105:R25–R29 (2000).
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(44)
| Title and authors |
Publication |
Year |
Angiotensin II type 2 receptor agonists: where should they be applied?
Koen Verdonk, A H Jan Danser, Joep H M van Esch
|
Expert Opin. Investig. Drugs
|
2012 |
Angiotensin II Type-1 Receptor-JAK/STAT Pathway Mediates the Induction of Visfatin in Angiotensin II-Induced Cardiomyocyte Hypertrophy :
Liang Chang, Rong Yang, Mei Wang, Jinming Liu, Yaling Wang, Hui Zhang, Yongjun Li
|
The American Journal of the Medical Sciences
|
2012 |
Angiotensin II and oxidative stress in the failing heart
Daniela K Zablocki, Junichi Sadoshima
|
Antioxidant Redox Signal
|
2012 |
Angiotensin type 2 receptor in hypertensive cardiovascular disease
Carmine Savoia, Michela DʼAgostino, Francesco Lauri, Massimo Volpe
|
Current Opinion in Nephrology and Hypertension
|
2011 |
Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies
Bianca C. Bernardo, Kate L. Weeks, Lynette Pretorius, Julie R. McMullen
|
Pharmacology & Therapeutics
|
2010 |
Mast cell chymase limits the cardiac efficacy of Ang I–converting enzyme inhibitor therapy in rodents
Chih-Chang Wei, Naoki Hase, Yukiko Inoue, Eddie W. Bradley, Eiji Yahiro, Ming Li, Nawazish Naqvi, Pamela C. Powell, Ke Shi, Yoshimasa Takahashi, Keijiro Saku, Hidenori Urata, Louis J. Dell’Italia, Ahsan Husain
|
J. Clin. Invest.
|
2010 |
The angiotensin AT2 receptor in left ventricular hypertrophy
U Muscha Steckelings, Robert E Widdop, Ludovit Paulis, Thomas Unger
|
Journal of Hypertension
|
2010 |
Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.
Y Li, Y Saito, K Kuwahara, X Rong, I Kishimoto, M Harada, M Horiuchi, M Murray, K Nakao
|
British Journal of Pharmacology
|
2010 |
Blockage of Angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation
M. S. Carneiro-Ramos, G. P. Diniz, A. P. Nadu, J. Almeida, R. L. P. Vieira, R. A. S. Santos, M. L. M. Barreto-Chaves
|
Basic Res Cardiol
|
2010 |
Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients
Matthias Huber, Heinz Völler, Stefanie Jakob, Rona Reibis, Van Do, Juliane Bolbrinker, Irina Zergibel, Roland E Schmieder, Andras Treszl, Karl Wegscheider, Reinhold Kreutz
|
Journal of Hypertension
|
2010 |
|